The Board of Directors has in-depth knowhow in drug development in the pharmaceutical and biotech industry.
Roger M Nitsch serves as CEO & President of Neurimmune. A neuroscientist with a background in medicine, he is recognized as a key opinion leader in neurodegenerative diseases with more than 30 years of experience in Alzheimer’s disease research, and as a pioneer in the development of therapeutic approaches for neurodegenerative diseases. The Potamkin prize winner and Member of the German Academy of Sciences holds a part-time professorship at the Institute for Regenerative Medicine (IREM), University of Zurich, Switzerland. Roger co-founded Neurimmune in 2006 together with Jan Grimm and Christoph Hock.
Christoph Hock is a board-certified psychiatrist and an internationally recognized expert on Alzheimer's disease and related disorders. He co-founded Neurimmune in 2006 and acts as Chief Medical Officer (CMO). Previously, Christoph served as Vice-President Medicine and Science on the executive board of the University of Zurich, and as member of the Swiss National Science Foundation's Research Council. He currently holds a part-time professorship on Biological Psychiatry at the Institute for Regenerative Medicine (IREM), University of Zurich.
Jan Grimm is a neuroscientist with 20 years of experience in drug discovery and development in US and European biotech. Jan co-founded Neurimmune in 2006, and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received a PhD degree from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.